Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in HIV patients with hyperlipidemia
NCT02833844Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of evolocumab in hyperlipidemia, mixed dyslipidemia, sponsored by Amgen. Started May 2017; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT02833844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833844.